SCHEMBL721435

SCHEMBL721435

O=C(O)C[C@](O)(C(=O)O)[C@H](O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACLY P53396 6/20 1.00
CPT2 P23786 1/20 1.00
HSPD1 P10809 1/20 0.46
BLM P54132 1/20 0.46
HSPE1 P61604 1/20 0.46
ALDH1A1 P00352 1/20 0.44
HMGCR P04035 1/20 0.39
CHRM1 P11229 1/20 0.39
TBXA2R P21731 1/20 0.39
ADRA1A P35348 1/20 0.39
CYP2D6 P10635 1/20 0.37
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37
HIF1A Q16665 1/20 0.37
TDP1 Q9NUW8 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2111332 1.00 ACLY (1.00) ACLYCPT2HSPD1BLMHSPE1
SCHEMBL6773065 1.00 ACLY (1.00) ACLYCPT2HSPD1BLMHSPE1
SCHEMBL17181773 1.00 ACLY (1.00) ACLYCPT2HSPD1BLMHSPE1
SCHEMBL17181757 1.00 ACLY (1.00) ACLYCPT2HSPD1BLMHSPE1
SCHEMBL2110910 1.00 ACLY (1.00) ACLYCPT2HSPD1BLMHSPE1
SCHEMBL27688847 1.00 ACLY (1.00) ACLYCPT2HSPD1BLMHSPE1
SCHEMBL108615 1.00 ACLY (1.00) ACLYCPT2HSPD1BLMHSPE1
SCHEMBL23068539 0.98 ACLY (0.95) ACLYCPT2HSPD1BLMHSPE1
Ammonia Solution, Strong SCHEMBL4780983 0.98 ACLY (0.95) ACLYCPT2HSPD1BLMHSPE1
SCHEMBL2821490 0.98 ACLY (0.95) ACLYCPT2HSPD1BLMHSPE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023074894-A1 CARTILAGE REGENERATION PROMOTER 小林製薬株式会社 2023-05-04 WO claimed
CN-115006378-A Medicine for preventing or treating metabolic diseases or metabolic dysfunction diseases 西安莱格瑞生物科技有限公司 2022-09-06 CN claimed
US-20150297545-A1 ORGANIC ACIDS AS AGENTS TO DISSOLVE CALCIUM MINERALS IN PATHOLOGICAL CALCIFICATION AND USES THEREOF UNIVERSITY OF HOUSTON SYSTEM (US) 2015-10-22 US claimed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
US-20020045769-A1 Novel acyclic chiral derivatives of hibiscus acid and the process of preparing the same DEPARTMENT OF SCIENCE AND TECHNOLOGY (IN) 2002-04-18 US claimed
US-20260124237-A1 CARTILAGE REGENERATION COMPOSITION KOBAYASHI PHARMACEUTICAL CO LTD (JP) 2026-05-07 US disclosed
WO-2023074893-A1 CARTILAGE REGENERATION COMPOSITION 小林製薬株式会社 2023-05-04 WO disclosed
WO-2023074895-A1 ORAL COMPOSITION 小林製薬株式会社 2023-05-04 WO disclosed
WO-2023074896-A1 PHARMACEUTICAL OR FOOD COMPOSITION 小林製薬株式会社 2023-05-04 WO disclosed
WO-2023074894-A1 CARTILAGE REGENERATION PROMOTER 小林製薬株式会社 2023-05-04 WO disclosed
CN-115006378-A Medicine for preventing or treating metabolic diseases or metabolic dysfunction diseases 西安莱格瑞生物科技有限公司 2022-09-06 CN disclosed
US-9351956-B1 Pharmaceutical composition comprising an enantiomer of lipoamide and derivatives thereof and method of use GeroNova Research Inc. (US) 2016-05-31 US disclosed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US disclosed
US-20120048295-A1 CLEANING FORMULATION FOR REMOVING RESIDUES ON SURFACES FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) 2012-03-01 US disclosed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US disclosed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US disclosed
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION L'OREAL (FR) 2009-01-29 US disclosed
US-20020045769-A1 Novel acyclic chiral derivatives of hibiscus acid and the process of preparing the same DEPARTMENT OF SCIENCE AND TECHNOLOGY (IN) 2002-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 ACLY 588/4885CPT2 405/4885HSPD1 1631/4885
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION CUTA, SYMPK, TPRKB ACLY 336/4885CPT2 790/4885HSPD1 2726/4885
US-20260124237-A1 CARTILAGE REGENERATION COMPOSITION CSGALNACT1, CD44, HCAR1 ACLY 3090/4885CPT2 3121/4885HSPD1 158/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA ACLY 175/4885CPT2 200/4885HSPD1 2595/4885
US-20020045769-A1 Novel acyclic chiral derivatives of hibiscus acid and the process of preparing the same ADH1A, ADH5, ADH1C ACLY 681/4885CPT2 881/4885HSPD1 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.